This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Monday's Small-Cap Winners & Losers

Gateway (GTW) ranked among the small-cap sector's big winners Monday, catapulting more than 50% in furious trading on M&A news.

Acer, a personal computer vendor based in Taiwan, agreed to snap up the Irvine, Calif., PC maker for $1.90 a share, or around $710 million. The all-cash deal, which represents a 57% premium to Gateway's latest closing price, should close by December.

Gateway shares surged 61 cents to $1.82, but the Russell 2000 still persisted downward, sliding 0.9% at 791.45. The S&P SmallCap 600 was off 0.7%.

Meanwhile another tech stock, Superconductor Technologies (SCON), rocketed 78% to $5.94 after announcing it's in talks to forge a joint venture with Hunchun BaoLi Communication, a China-based maker of push-to-talk handsets, by the end of 2007.

Superconductor, based in Santa Barbara, Calif., said the proposed joint venture "would focus primarily on the manufacturing and marketing of [its] SuperLink interference elimination solution for the Chinese market."

ID Systems (IDSY) jumped after saying Wal-Mart (WMT) has ordered its Wireless Asset Net industrial vehicle-management system for 13 more Wal-Mart sites under an existing 2006 agreement, which originally involved eight facilities. Shares of the Hackensack, N.J., company were up $1.73, or 17%, to $11.89. Wal-Mart stock recently ticked up 8 cents at $43.82.

On the flip side, biopharma Neurochem (NRMX) lost 43% after its Alzheimer's disease treatment, Alzhemed (generically called tramiprosate), didn't achieve the primary endpoints in its North American late-phase study, per top-line results.

The Canada-based company also said "it is not possible to draw definitive conclusions" on the drug's effects "due to significant interference from high between-site variations that complicated the statistical analyses beyond expectations." Given this, the Food and Drug Administration "advised that neither the proposed adjusted models nor any further adjustments could be used for this trial to provide results in support of a claim of clinical efficacy." Neurochem shares were down $2.40 to $3.16.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs